A dose-finding study of oxytocin using neurophysiological measures of social processing.

Wynn JK, Green MF, Hellemann G, Reavis EA, Marder SR

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology28 Jul 2018Cited by 34 (Europe PMC)

PMID30082892PMCIDPMC6300532DOI10.1038/s41386-018-0165-yPepBankPUB-30082892

Source link PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialMechanism
In patients with schizophrenia, intranasal oxytocin had no drug effect on pupil dilation in response to faces at any dose versus placebo.
In plain wordsIn people with schizophrenia, oxytocin spray did not change pupil size responses to faces at any dose, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changePupil dilation to affective faces
Study
n = 47
Comparator
Placebo
Outcome group
Brain and neuronal activity · Nervous system and cognition
Studied dose
8-84 IU · intranasalAs given in this study (human).
Source sentences
Summary
Significant pupil dilation was observed in response to faces vs. non-face stimuli, though there were no drug effects at any dose.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we conducted a double-blind, placebo-controlled, cross-over dose ranging study of OT.
Summary · context
In total 47 patients with schizophrenia were randomly assigned to one of eight doses of OT (8, 12, 24, 36, 48, 60, 72, or 84 IU).
Report a problemFND-3008289204
02HumanRandomized controlled trialMechanism
In patients with schizophrenia, 36 IU of intranasal oxytocin significantly enhanced Mu-suppression to social stimuli versus placebo.
In plain wordsIn people with schizophrenia, a 36 IU dose of oxytocin spray strengthened a brain signal for social processing, compared with placebo.
Peptide
Oxytocin
Outcome
IncreaseMu-suppression at 36 IU
Study
n: not reported in source
Comparator
Placebo
Outcome group
Brain and neuronal activity · Nervous system and cognition
Studied dose
36 IU · intranasalAs given in this study (human).
Source sentences
Summary
Mu-suppression, i.e., suppression of oscillations in the 8-12 Hz range over central electrodes in response to social stimuli, was significantly enhanced at doses of 36 and 48 IU in comparison to placebo, but not at other doses.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we conducted a double-blind, placebo-controlled, cross-over dose ranging study of OT.
Summary · context
In total 47 patients with schizophrenia were randomly assigned to one of eight doses of OT (8, 12, 24, 36, 48, 60, 72, or 84 IU).
Report a problemFND-3008289201
03HumanRandomized controlled trialMechanism
In patients with schizophrenia, 48 IU of intranasal oxytocin significantly enhanced Mu-suppression to social stimuli versus placebo.
In plain wordsIn people with schizophrenia, a 48 IU dose of oxytocin spray strengthened a brain signal for social processing, compared with placebo.
Peptide
Oxytocin
Outcome
IncreaseMu-suppression at 48 IU
Study
n: not reported in source
Comparator
Placebo
Outcome group
Brain and neuronal activity · Nervous system and cognition
Studied dose
48 IU · intranasalAs given in this study (human).
Source sentences
Summary
Mu-suppression, i.e., suppression of oscillations in the 8-12 Hz range over central electrodes in response to social stimuli, was significantly enhanced at doses of 36 and 48 IU in comparison to placebo, but not at other doses.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we conducted a double-blind, placebo-controlled, cross-over dose ranging study of OT.
Summary · context
In total 47 patients with schizophrenia were randomly assigned to one of eight doses of OT (8, 12, 24, 36, 48, 60, 72, or 84 IU).
Report a problemFND-3008289202
04HumanRandomized controlled trialMechanism
In patients with schizophrenia, intranasal oxytocin at the other tested doses did not significantly enhance Mu-suppression versus placebo.
In plain wordsIn people with schizophrenia, the other oxytocin spray doses did not strengthen the brain signal for social processing, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeMu-suppression at other doses
Study
n: not reported in source
Comparator
Placebo
Outcome group
Brain and neuronal activity · Nervous system and cognition
Studied dose
8, 12, 24, 60, 72 and 84 IU · intranasalAs given in this study (human).
Source sentences
Summary
Mu-suppression, i.e., suppression of oscillations in the 8-12 Hz range over central electrodes in response to social stimuli, was significantly enhanced at doses of 36 and 48 IU in comparison to placebo, but not at other doses.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, we conducted a double-blind, placebo-controlled, cross-over dose ranging study of OT.
Summary · context
In total 47 patients with schizophrenia were randomly assigned to one of eight doses of OT (8, 12, 24, 36, 48, 60, 72, or 84 IU).
Report a problemFND-3008289203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 1/2NCT03863288

Dose Response Relationship of Oxytocin on Irritability in Youths

University of Nebraskan = 6018 Feb 2022 to 27 Feb 2024

Irritable Mood

Trial page ClinicalTrials.govUpdated 14 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:49 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.